NCT06254261RecruitingPhase 2
A Study of RAY1225 in Participants With Obesity
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants With Obesity
Source: ClinicalTrials.gov · Last updated 19 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- First submitted
- 3 Feb 2024
- Start date
- 21 Feb 2024
- Primary completion date
- 20 Dec 2025
- Lead sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Diseases
- Obesity
- NCT number
- NCT06254261
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 270
- From 21 Feb 2024 to the primary completion date, 20 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
Other illness
- Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
- with a history of diabetes or hypoglycemia;
- Have a family or personal history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia (MEN) Syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator.
- allergic constitution;
Other
- not suitable for subcutaneous injection.
Who the study is looking for
- Have a body mass index (BMI) of ≥28 kilogram per square meter (kg/m²) or ≥24 kg/m² and previously diagnosed with at least one of the following weight related comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, fatty liver disease,or HbA1c ≥5.7% and \< 6.5%;
- Participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijingcun | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.